![Moshe Manor](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Moshe Manor
Direktor/Vorstandsmitglied bei
Kamedis
Profil
Moshe Manor is currently a Director at Kamedis.
Prior to this, he was the President, Chief Executive Officer & Director at Protalix Biotherapeutics, Inc. from 2014 to 2019.
He was also the President-Asia & Pacific Region at Teva Pharmaceutical Industries Ltd. from 1984 to 2012.
In addition, he served as Chairman at MEway Pharma Ltd. and Director at Coronis Partners Ltd. Mr. Manor holds an MBA from Tel-Aviv University and an undergraduate degree from The Hebrew University of Jerusalem.
Aktive Positionen von Moshe Manor
| Unternehmen | Position | Beginn |
|---|---|---|
Kamedis
 Kamedis Household/Personal CareConsumer Non-Durables Develops skin care products and sells through online store | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Moshe Manor
| Unternehmen | Position | Ende |
|---|---|---|
| PROTALIX BIOTHERAPEUTICS, INC. | Vorstandsvorsitzender | 30.06.2019 |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Corporate Officer/Principal | 01.01.2012 |
Coronis Partners Ltd.
 Coronis Partners Ltd. Investment ManagersFinance Coronis Partners focuses on pharmaceuticals, diagnostics and nanotechnology. They invest in companies that are likely to grow in size in the range of $100 million to $200 million within 4 to 5 years. Companies should expect a major financial event, such as an IPO, within 2 to 3 years. Coronis Partners always require a board seat and they avoid repeated investments in companies in the same field or sector. | Direktor/Vorstandsmitglied | - |
MEway Pharma Ltd.
 MEway Pharma Ltd. Medical SpecialtiesHealth Technology Operates as a medical device development company | Vorsitzender | - |
Ausbildung von Moshe Manor
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
63
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Teva Pharmaceutical Industries Ltd.
 Teva Pharmaceutical Industries Ltd. Pharmaceuticals: GenericHealth Technology Manufactures and markets generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients | Health Technology |
Tel-Aviv University
 Tel-Aviv University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Hebrew University of Jerusalem
 The Hebrew University of Jerusalem Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Protalix Biotherapeutics, Inc.
 Protalix Biotherapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets recombinant therapeutic proteins | Health Technology |
Coronis Partners Ltd.
Coronis Partners Ltd. Investment ManagersFinance Coronis Partners focuses on pharmaceuticals, diagnostics and nanotechnology. They invest in companies that are likely to grow in size in the range of $100 million to $200 million within 4 to 5 years. Companies should expect a major financial event, such as an IPO, within 2 to 3 years. Coronis Partners always require a board seat and they avoid repeated investments in companies in the same field or sector. | Finance |
Kamedis
Kamedis Household/Personal CareConsumer Non-Durables Develops skin care products and sells through online store | Consumer Non-Durables |
MEway Pharma Ltd.
MEway Pharma Ltd. Medical SpecialtiesHealth Technology Operates as a medical device development company | Health Technology |
